INHIBITION OF HUMAN-LEUKOCYTE ELASTASE (HLE) BY N-SUBSTITUTED PEPTIDYL TRIFLUOROMETHYL KETONES

被引:89
作者
SKILES, JW
FUCHS, V
MIAO, C
SORCEK, R
GROZINGER, KG
MAULDIN, SC
VITOUS, J
MUI, PW
JACOBER, S
CHOW, G
MATTEO, M
SKOOG, M
WELDON, SM
POSSANZA, G
KEIRNS, J
LETTS, G
ROSENTHAL, AS
机构
[1] BOEHRINGER INGELHEIM PHARMACEUT INC, DEPT PHARMACOL, RIDGEFIELD, CT 06877 USA
[2] BOEHRINGER INGELHEIM PHARMACEUT INC, DEPT MED CHEM, RIDGEFIELD, CT 06877 USA
[3] BOEHRINGER INGELHEIM PHARMACEUT INC, DEPT BIOCHEM, RIDGEFIELD, CT 06877 USA
关键词
D O I
10.1021/jm00082a005
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of tripeptides possessing trifluoromethyl or aryl ketone residues at P1 were prepared and evaluated both in vitro and in vivo as potential inhibitors of human leukocyte elastase (HLE). Tripeptides containing non naturally occurring N-substituted glycine residues at the P2-position have been demonstrated to be potent in vitro inhibitors of HLE, with IC50 values in the submicromolar range. Sterically demanding substituents on the P2-nitrogen have no detrimental effect on in vitro potency. The inhibition process presumably acts via hemiketal formation with the active site Ser195 of HLE, and is facilitated by the strongly electron withdrawing trifluoromethyl functionality. Deletion of the amino acid at the P3-subsite region affords inactive compounds. Valine is the preferred residue at the P1-position, whereas the corresponding glycine, alanine, alpha,alpha-dimethylglycine, or phenylalanine analogues are all inactive. The compounds described herein all confer a high degree of in vitro specificity when tested against representative cysteine, aspartyl, metallo, and other serine proteases. One of the most potent in vitro inhibitors is (3RS)-N-[4-[[[(4-chlorophenyl)sulfonyl]amino]carbonyl]phenyl]oxomethyl]-L-valyl-N-(2,3-dihydro-1H-inden-2-yl)glycine N-[3-(1,1,1-trifluoro-4-methyl-2-oxopentyl)]amide (20i; BI-RA-260) (IC50 = 0.084-mu-M). Compound 20i was also tested in hamsters in an elastase-induced pulmonary hemorrhage (EPH) model. In this model, intratracheal (it.) administration of 20i, 5 min prior to HLE challenge, effectively inhibited hemorrhage in a dose-dependent manner with an ED50 of 4.8-mu-g. The inhibitor 20i, 20-mu-g administered it. 24, 48, and 72 h prior to HLE challenge, exhibits significant inhibition against hemorrhage at all time points (97%, 64% and 49%, respectively). In a 21-day chronic model of emphysema in hamsters, 200-mu-g of HLE administered it. caused an elastase-induced emphysema in the lungs which can be quantitated histologically utilizing image analysis. In this assay, 20i significantly inhibited pulmonary lesions associated with septal destruction and increased alveolar spaces, when dosed at 20-mu-g it. 5 min prior to challenge with HLE.
引用
收藏
页码:641 / 662
页数:22
相关论文
共 88 条
[1]   ENZYME-INHIBITORS - GROUND-STATE TRANSITION-STATE ANALOGS [J].
ABELES, RH .
DRUG DEVELOPMENT RESEARCH, 1987, 10 (04) :221-234
[2]   CONFORMATIONAL-ANALYSIS .130. MM2 - HYDROCARBON FORCE-FIELD UTILIZING V1 AND V2 TORSIONAL TERMS [J].
ALLINGER, NL .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1977, 99 (25) :8127-8134
[3]  
AN-ZHI W, 1988, Febs Letters, V234, P367, DOI 10.1016/0014-5793(88)80118-2
[4]   KINETIC AND CHEMICAL EVIDENCE FOR THE INABILITY OF OXIDIZED ALPHA-1-PROTEINASE INHIBITOR TO PROTECT LUNG ELASTIN FROM ELASTOLYTIC DEGRADATION [J].
BEATTY, K ;
MATHESON, N ;
TRAVIS, J .
HOPPE-SEYLERS ZEITSCHRIFT FUR PHYSIOLOGISCHE CHEMIE, 1984, 365 (07) :731-736
[5]  
BERGESON S, 1986, Patent No. 189305
[6]   COMPUTER-PROGRAM FOR THE PARAMETRIC AND NONPARAMETRIC COMPARISON OF SEVERAL GROUPS TO A CONTROL [J].
BLAKER, WD .
COMPUTERS IN BIOLOGY AND MEDICINE, 1987, 17 (01) :37-44
[7]   X-RAY CRYSTAL-STRUCTURE OF THE COMPLEX OF HUMAN-LEUKOCYTE ELASTASE (PMN ELASTASE) AND THE 3RD DOMAIN OF THE TURKEY OVOMUCOID INHIBITOR [J].
BODE, W ;
WEI, AZ ;
HUBER, R ;
MEYER, E ;
TRAVIS, J ;
NEUMANN, S .
EMBO JOURNAL, 1986, 5 (10) :2453-2458
[8]   HUMAN-LEUKOCYTE AND PORCINE PANCREATIC ELASTASE - X-RAY CRYSTAL-STRUCTURES, MECHANISM, SUBSTRATE-SPECIFICITY, AND MECHANISM-BASED INHIBITORS [J].
BODE, W ;
MEYER, E ;
POWERS, JC .
BIOCHEMISTRY, 1989, 28 (05) :1951-1963
[9]  
BOGARD WC, 1980, J BIOL CHEM, V255, P6569
[10]   PHARMACOLOGICAL PROFILE OF THE SUBSTITUTED BETA-LACTAM L-659,286 - A MEMBER OF A NEW CLASS OF HUMAN-PMN ELASTASE INHIBITORS [J].
BONNEY, RJ ;
ASHE, B ;
MAYCOCK, A ;
DELLEA, P ;
HAND, K ;
OSINGA, D ;
FLETCHER, D ;
MUMFORD, R ;
DAVIES, P ;
FRANKENFIELD, D ;
NOLAN, T ;
SCHAEFFER, L ;
HAGMANN, W ;
FINKE, P ;
SHAH, S ;
DORN, C ;
DOHERTY, J .
JOURNAL OF CELLULAR BIOCHEMISTRY, 1989, 39 (01) :47-53